Skip to content
NBlaz – Lifestyle
Author:
Cardurion Pharmaceuticals
Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure
October 11, 2026